17413-82-0Relevant academic research and scientific papers
Discovery of (E)-4-styrylphenoxy-propanamide: A dual PPARα/γ partial agonist that regulates high-density lipoprotein-cholesterol levels, modulates adipogenesis, and improves glucose tolerance in diet-induced obese mice
Dutra, Luiz A.,Lacerda, Mariella G.,Destro Inácio, Maiara,Martins, Johnny W.L.,Lopes Silva, Ana C.,Bento da Silva, Patricia,Chorilli, Marlus,Amato, Angélica A.,Baviera, Amanda M.,Passarelli, Marisa,Guido, Rafael V.C.,Dos Santos, Jean L.
, (2022/01/26)
Peroxisome proliferator-activated receptors are promising therapeutic targets for metabolic diseases, including obesity, diabetes, and dyslipidemia. This study describes the design, synthesis and pharmacological evaluation of stilbene-based compounds as d
Effect of stilbene and chalcone scaffolds incorporation in clofibric acid on PPARα agonistic activity
Giampietro, Letizia,D'Angelo, Alessandra,Giancristofaro, Antonella,Ammazzalorso, Alessandra,De Filippis, Barbara,Di Matteo, Mauro,Fantacuzzi, Marialuigia,Linciano, Pasquale,Maccallini, Cristina,Amoroso, Rosa
, p. 59 - 65 (2014/01/17)
In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, new compounds based on a combination of clofibric acid, the active metabolite of clofibrate, and trans-stilbene, chalcone, and other lipophilic groups were synthesized. They were evaluated for PPARα transactivation activity; all branched derivatives showed an increase of the transcriptional activity of receptor compared to the linear ones. Noteworthy, stilbene and benzophenone branched derivatives activated the PPARα better than clofibric acid.
